Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.56 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.56 |
| ▸ | GSR | P00390 | 1/20 | 0.59 |
| ▸ | MMP2 | P08253 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amphetamine SCHEMBL578608 | 1.00 | GSR (0.59) | GSRMMP2SLC6A2TAAR1MAOA | |
| Amphetamine SCHEMBL28843066 | 1.00 | GSR (0.59) | GSRMMP2SLC6A2TAAR1MAOA | |
| Amphetamine SCHEMBL27917387 | 1.00 | GSR (0.59) | GSRMMP2SLC6A2TAAR1MAOA | |
| Amphetamine SCHEMBL969267 | 0.99 | GSR (0.57) | GSRMMP2SLC6A2TAAR1MAOA | |
| Amphetamine SCHEMBL4563535 | 0.95 | SLC6A2 (0.58) | GSRMMP2SLC6A2TAAR1MAOA | |
| Dextroamphetamine SCHEMBL19873157 | 0.93 | THRB (0.59) | GSRMMP2SLC6A2TAAR1MAOA | |
| Amphetamine SCHEMBL27878191 | 0.93 | THRB (0.59) | GSRMMP2SLC6A2TAAR1MAOA | |
| Amphetamine SCHEMBL973960 | 0.93 | THRB (0.59) | GSRMMP2SLC6A2TAAR1MAOA | |
| Amphetamine SCHEMBL969812 | 0.93 | THRB (0.59) | GSRMMP2SLC6A2TAAR1MAOA | |
| Lysine SCHEMBL19873156 | 0.93 | MMP2 (0.54) | GSRMMP2SLC6A2TAAR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116710084-A | Use of mGluR5 antagonists for the treatment of amphetamine addiction | 诺华股份有限公司 | 2023-09-05 | — | — | CN | claimed |
| CN-109912683-B | Cytotoxin molecule, conjugate, preparation method and application thereof | 杭州多禧生物科技有限公司 | 2023-01-06 | — | — | CN | claimed |
| CN-112533595-A | Method for treating substance abuse | 感知神经科学公司 | 2021-03-19 | — | — | CN | claimed |
| CN-110191706-A | The treatment method for treating lidocaine invalid illness and hypokalemia illness | 阿卡利德公司 | 2019-08-30 | — | — | CN | claimed |
| CN-110167562-A | DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC are directed to the protective effect for causing the drug of ion channel disease | 萨恩帕斯药物有限公司 | 2019-08-23 | — | — | CN | claimed |
| CN-106163514-B | Agent for preventing and treating attention deficit and hyperactivity disorder | 藤本株式会社 | 2019-07-19 | — | — | CN | claimed |
| CN-109912683-A | Cytotoxin molecule, conjugate, preparation method and application thereof | 杭州多禧生物科技有限公司 | 2019-06-21 | — | — | CN | claimed |
| CN-109843331-A | Protective effects of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs causing ion channel diseases | 萨恩帕斯药物有限公司 | 2019-06-04 | — | — | CN | claimed |
| CN-106163514-A | Agent for preventing and treating attention deficit and hyperactivity disorder | 藤本株式会社 | 2016-11-23 | — | — | CN | claimed |
| CN-103298455-A | Combination therapy of lysine amphetamine and extended release guanfacine | SHIRE LLC | 2013-09-11 | — | — | CN | claimed |
| CN-103221535-A | Use of adenosine receptor signaling to modulate blood brain barrier permeability | UNIV CORNELL | 2013-07-24 | — | — | CN | claimed |
| CN-118338916-A | Multifunctional compounds for use in medical imaging and therapy | 安特络手术解决方案公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-112964625-B | Cell population analysis | 英国质谱公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118121577-A | Method for treating substance abuse | 感知神经科学公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-117529665-A | Amphetamine carbamate compounds and methods | 诺芬药品公司 | 2024-02-06 | — | — | CN | disclosed |
| WO-2005032474-A2 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OF OVERDOSE OR ABUSE | NEW RIVER PHARMACEUTICALS INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050054561-A1 | Abuse-resistant amphetamine compounds | NEW RIVER PHARMACEUTICALS INC. | 2005-03-10 | — | — | US | disclosed |
| US-20050038121-A1 | Abuse resistant lysine amphetamine compounds | NEW RIVER PHARMACEUTICALS INC. (US) | 2005-02-17 | — | — | US | disclosed |
| US-20050038121-A1 | Abuse resistant lysine amphetamine compounds | NEW RIVER PHARMACEUTICALS INC. (US) | 2005-02-17 | — | — | US | disclosed |
| WO-2005000334-A1 | ABUSE RESISTANT AMPHETAMINE COMPOUNDS | NEW RIVER PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054561-A1 | Abuse-resistant amphetamine compounds | COMT, CYP3A5, SLC6A2 | SLC6A2 3/4885SLC6A3 4/4885GSR 2109/4885 |
| US-20050038121-A1 | Abuse resistant lysine amphetamine compounds | COMT, KDM6B, KDM5B | SLC6A2 31/4885SLC6A3 33/4885GSR 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.